logo

ANVS

Annovis Bio·NYSE
--
--(--)
--
--(--)
3.51 / 10
Netural

Annovis Bio's fundamental analysis yields a neutral rating with a composite score of 3.5/10. Key positives include a strong inventory turnover ratio (47.88) and an interest coverage ratio (EBIT/Interest expense) of 15.51, both in favorable quartiles. However, the PB-ROE factor of 1.29 and negative Asset-MV value (-0.507) signal potential overvaluation or weak profitability, tempering the overall outlook. Revenue growth is robust YoY, but the net profit to total profit ratio at 100% may reflect one-off items rather than recurring earnings. The historical backtest results for each factor show mixed returns, reinforcing the need for a balanced view.

Fundamental(3.51)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight22.92%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.48%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-1.91%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight18.40%
1M Return8.99%
PB-ROE
Value1.29
Score1/3
Weight18.60%
1M Return8.79%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-1.99%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.17%
1M Return0.10%
Asset-MV
Value-0.51
Score2/3
Weight26.23%
1M Return12.15%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.57%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight17.66%
1M Return8.80%
Is ANVS undervalued or overvalued?
  • ANVS scores 3.51/10 on fundamentals and holds a Fair valuation at present. Backed by its -169.34% ROE, 0.00% net margin, -2.18 P/E ratio, 5.02 P/B ratio, and 64.99% earnings growth, these metrics solidify its Netural investment rating.